Seasonal variation in uterotonic activity of Rhoicissus tridentata extracts by Katsoulis, LC et al.
SEASONAL VARIATION IN 
UTEROTONIC ACTIVITY OF 
RHOICISSUS TRIDENTATA 
EXTRACTS 
L C Katsoulis, D J H Veale, I Havlik 
Background. Rhoicissus tridentata lignotubers are widely used 
in southern African traditional pregnancy-related remedies. 
Objectives. To determine the seasonal variation in contractile 
activity of extracts from different parts of the plant. 
Methods. Isolated rat uterus tissue was used to compare the 
contractile activity of crude aqueous extracts of R. tridentata 
made from plant material harvested every 3 months over a 
period of 2 years. 
Results and conclusions. The activity of the plant extracts 
from plants harvested in summer and autumn were 4 - 5-
fold higher than extracts from plants harvested in winter or 
spring. The tubers stimulated the greatest degree of contrac-
tions, followed by the stems, roots and leaves. These results 
highlight the need to standardise the timing of harvesting 
R. tridentata. 
S Afr Med J 2002; 92: 375-377. 
Decoctions of the roots and lignotubers of Rhoicissus tridentata 
(subsp. cuneifolia) are used by southern African women in 
ethnic herbal remedies for delayed childbirth and to facilitate 
childbirth.'" R. tridentata decoctions are prepared by boiling 
dried milled roots or lignotubers for approximately an hour. 
This is done by traditional healers who sell the bottled 
decoctions. The plant is widely distributed throughout the 
eastern portion of southern Africa,' and is found in most 
traditional healer vending stores around Johannesburg. 
Pharmacological investigations using isolated rat uterus and 
ileum suggest that the contractile response to hot water plant 
extracts may be mediated by muscarinic receptors and the 
stimulation of prostaglandin synthesis.' While doing 
preliminary work on the pharmacology of the plant extracts it 
became evident that there was a high degree of variability in 
the activity of extracts from different plant samples. 
The pharmacological response to R. tridentata has been shown 
to vary geographically. The plant extracts acted either 
agonistically or antagonistically on muscarinic receptors 
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depending on where the plant was harvested.' Temporal 
variation is another possible source of variability in chemical 
constituents and biological activity of plants. This is a well-
documented phenomenon.'·' The expression of genes coding 
for chemical constituents of plants is under the control of 
various factors, such as the developmental stage of the 
organism, duration and intensity of light, nutrient supply, 
triggering of internal signals and sequential expression of 
genes coding for secondary metabolites.' All the above factors 
vary temporally, which in turn causes seasonal fluctuations in 
the levels of both primary and secondary metabolites within 
plant tissues. 
The aim of this study was to determine whether the 
contractile activity of R. tridentata varies seasonally. 
METHODS 
R. tridentata subsp. cuneifolia plant material was collected from 
Suikerbosrand Nature Reserve, 60 km south of Johannesburg. 
Three plants were harvested every 3 months from May 1996 to 
April 1998. The identity of the plants was validated by 
L Katsoulis, and one voucher specimen for each individual 
plant harvested was lodged in the C E Moss Herbarium 
(voucher specimen numbers of the three plants: 086928, 082929 
and 082930). 
Milled plant material was boiled for an hour, settled, and 
the supernatant lyophilised. Sections of uterine tissue obtained 
from the central portion of the uterine horns of oestrogenised 
virgin Sprague-Dawley rats were mounted in 50 ml organ 
baths containing aerated (5% C02 in 0 2) Tyrode solution. The 
uterine tissue was maintained at 26°C to decrease spontaneous 
contractility. The organs were rinsed repeatedly while being 
allowed to return to baseline, before any investigations. 
Control challenges with acetylcholine were done between each 
test challenge. The activity of the extracts was tested by 
incubating the tissues with 1.3 mg/ml of the various plant 
extracts for 5 minutes before adding acetylcholine 
cumulatively. This was done to determine whether the plant 
extracts alter the organ's response to acetylcholine. Isotonic 
contractions were measured against 1 g resistance and 
expressed relative to the maximal response of the same tissues 
to acetylcholine. More details of the methods are given in the 
study by Veale et al.' 
RESULTS AND DISCUSSION 
Fig. 1 illustrates how the different parts of the plants harvested 
in winter and spring all yielded aqueous extracts with low 
levels of contractile activity, whereas the extracts from different 
parts of the plants harvested during summer and autumn were 
considerably more active. During summer the tubers yielded 
the most active aqueous extracts, followed by the stems, roots 
and leaves. The autumn plants exhibited a similar pattern of 
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Fig. 1. Dose response curves of isolated rat uterus when pre-treated with 1.3 mg/ml aqueous extracts of all parts of Rhoicissus tridentata subsp. 
cuneifolia harvested during spring before the cumulative addition of acetylcholine. Each point represents the mean with the vertical bars 
representing the standard error of the mean (SEM). 
variation except that the roots were the least active part. The 
autumn and summer tubers were four and five times more 
active than the winter and spring extracts. The stems displayed 
similar seasonal variability. 
Statistical differences between the direct contractile activity 
of the plants, shown by 'Rh' on the dose response curves, are 
given in Table I. · 
All parts of the plant harvested in summer and autumn 
were able to stimulate contractions of the isolated uterus 
directly. Traditional healers usually use the lignotubers, which 
yield the most uterotonically active extracts. The activity of the 
tuber extracts is highest during the growing season and 
decreases during the seasons when the plant is dormant. 
Table I. Statistical differences .between the contractile activity of 
extracts from different parts of Rhoicissus plants harvested during 
different seasons 
Tubers ,. 
Spring v .. summ.er 
Spring v. autumn t 
Summer v. win~r t 
Aµ\ufiU1 v. winter* 
Roots Stems 
Spring ~. sµmmer * Spring v. summert 
Summer v. autumn* 
Autumn v. wintert 
May 2002, Vol. 92, No. 5 SAM] 
The root and stem extracts showed a similar pattern in 
seasonal variation in uterotonic activity to that of the tuber 
extracts. That is, the activity of the extracts started increasing 
when plants were harvested after the first rains. The activity 
increased throughout the growing season (or rainy season), 
reaching a peak in autumn. The activity of the extracts then fell 
as the plants lost their leaves and became dormant during 
winter. The rise in activity as the rains started could have been 
caused by the improved uptake of minerals from the soil 
following the mineralisation flush after the first rains, which 
usually leads to a sharp rise in the nitrogen content within the 
plant.10 
Variability in the contractile activity of the extracts could 
have been caused by: (i) altered concentrations of the active 
principle(s); (ii) a change in the quality or nature of the active 
principle(s); or (iii) changes in the production of compounds 
such as saponins which may have altered extraction of the 
pharmacologically active component(s). 
RELEVANCE TO CONSERVATION 
The stem extracts yielded a similar response to the most active 
part, namely the lignotubers. This is significant from an 
environmental perspective, as harvesting stems for the trade in 
traditional remedies would have a much lower impact on the 
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plant populations of R. tridentata than harvesting the 
lignotubers and roots. With current use of the lignotubers, the 
plant has to be uprooted for lignotubers to be harvested. 
CLINICAL RELEVANCE 
Variability in the uterine response to the decoctions from 
different seasons highlights a severe flaw in the use of 
traditional herbal remedies. Collectors and vendors have no 
way of determining the chemical composition of the plant 
material harvested. Eight traditional healers in and around 
Johannesburg were questioned on whether they were aware of 
any seasonal variation in the efficacy of R. tridentata. None of 
them seemed to be aware of the concept. 
Traditional healers were also unaware of any toxic effects of 
the plant (personal communication) despite reports implicating 
the plant in fatal poisonings. 11 •12 This suggests that only certain 
plant samples may be toxic. It is possible that the toxicity of the 
plant also fluctuates seasonally, which would explain why 
traditional healers are generally unaware of the toxic potential 
of R. tridentata. Further investigation should be done to 
determine whether the poisonings that have occurred are 
concentrated at a certain time of the year. 
Variability in the pharmacological activity ofR. tridentata 
also reiterates the well-accepted importance of standardisation 
criteria that need to be established for herbal remedies. The 
results also support the suggestion by Tobler1' that there should 
be a holistic approach to standardising the production of 
medicinal plants by controlling the entire production process 
for medicinal plants, starting from cultivation and continuing 
the control through the processing of the plant material. 
References 
1. Veale DJH, Furman KI, Oliver OW. South African traditional herbal medicines used during 
pregnancy and childbirth. ] Ethnopharmacol 1992; 36: 185-191. 
2. Varga CA, Veale DJH. Isihlambezo - utilization patterns and potential health effects. Soc Sci 
Med 1997; 44: 911-924. 
3. van Wyk BE, van Oudtshoorn B, Gericke N. Medicinal Plants of South Africa. Pretoria: Briza 
Publications, 1997. 
4. Katsoulis LC, Veale DJH, Havlik I. The pharmacological action of Rhoicissus tridentata on 
isolated rat uterus and ileum. Phytother Res 2000; 14: 460-462. 
5. Katsoulis LC Rhoicissus tridentata subsp cuneifolia: the effect of geographical distribution and 
plant storage on rat uterine contractile activity. S Afr J Bot 1999; 65: 299-302. 
6. Bos R, Woerdenbag HJ, van Putten FM, Hendriks H, Scheffer JJ. Seasonal variation of the 
essential oil, valerenic acid and derivatives, and velopotriates in Valeriana officinalis roots and 
rhizomes, and the selection of plants suitable for phytomedicines. Planta Med 1998; 64: 143-
147. 
7. Dolling A, Zackrisson 0, Nilsson MC. Seasonal variation in phytotoxicity of bracken 
(Pteridium aquilinum L. Khun). Journal of Chemical Ecology 1994; 20: 3163-3172. 
8. Luckner M. Expression and control of secondary metabolism. In: Bell EA, Charlwood BV, 
eds. Encyclopaedia of Plant Physiology. New Series, Vol. 8 Secondary Plant Metabolites. New 
York: Springer-Verlag, 1980: 23-50. 
9. Veale DJH, Oliver DW, Arangies NS, Furman KI. Preliminary isolated organ studies using an 
aqueous extract of Clivia miniata leaves. J Ethnopharmacol 1989; 27: 341-346. 
10. Birch HF. Nutrification after periods of dryness. Plant Soil 1960; 12: 81-96, 
11. Watt JM, Breyer-Brandwijk MJ. The Medicinal and Poisonous Plants of Southern and Eastern 
Africa. 2nd ed. Edinburgh: E and S Livingston, 1962: 1055-1056. 
12. Brandt HC, Muller GJ. Traditional medicines and acute poisoning. Continuing Medical 
Education 1995; 13: 1053-1060. 
13. Tobler M. Characteristics of whole fresh plant extracts. Part 2: Holistic standardisation. 
Ganzheits Medizin Journal Suisse de Medecine Holistique 1994; 5: 296-300. 
Accepted 4 November 2001. 
PATHOGENIC MECHANISM OF 
TYPE 2 DIABETES IN GHANAIANS 
- THE IMPORTANCE OF BETA CELL 
SECRETION, INSULIN SENSITIVITY 
AND GLUCOSE EFFECTIVENESS 
Albert G B Amoah, Samuel K Owusu, Dara P Schuster, 
Kwame Osei 
Objective. To assess insulin sensitivity and beta cell secretion 
in indigenous Ghanaian subjects with a spectrum of glucose 
intolerance. 
Research and methods. We evaluated beta cell secretion, insulin 
sensitivity (Si) and glucose effectiveness (Sg) in three groups: 
group l, 15 healthy control subjects without family history of 
type 2 diabetes; group 2, 11 healthy non-diabetic first-degree 
relatives of Ghanaian patients with type 2 diabetes; and 
group 3, 10 patients with type 2 diabetes living in Accra, 
Ghana, West Africa. A standard oral glucose tolerance test 
(OGTT) and frequently sampled intravenous glucose 
tolerance (FSIGT) test were performed for each subject. Si and 
Sg were measured using Bergman's minimal model method. 
Results. The mean body mass index (BMI) and lean body 
mass were not different among the three groups. However, 
the waist-to-hip circumference ratio, total body fat as well as 
triceps and biceps skinfolds were significantly greater in 
group 3 (diabetic patients) than in group 2 (relatives) and 
group 1 (healthy controls). Mean fasting and postprandial 
serum glucose levels were not significantly different between 
the relatives and healthy controls during oral glucose 
challenge. The mean fasting and postprandial serum glucose 
levels were significantly higher in the group 3 diabetic patients 
than in the non-diabetic groups. Mean fasting serum insulin 
and C-peptide levels tended to be higher in group 3 than in 
groups 1 and 2. However, mean serum insulin and C-peptide 
responses after oral glucose load were significantly greater in 
group 2 than in the group 1 healthy controls. The insulin 
responses in the two non-diabetic groups after oral glucose 
challenge were significantly greater than in the diabetic 
patients. During the FSIGT, the mean serum glucose 
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responses were similar in the two non-diabetic groups 
(groups 1and2). The serum glucose responses were 
significantly greater iri group 3 than in the non-diabetic 
groups. Mean total and acute first and second phases of 
insulin and C-peptide responses were greater in group 2 than 
group L However, acute phases of insulin secretion were 
severely blunted in group 3 when compared with groups 1 
and 2 during FSIGT in our Ghanaians. We found that the 
mean Si was slightly lower in group 2 (1.72 ± 0.32) than in the 
healthy controls in group 1 (1.9 ± 0.55, P =NS). Mean Si was 
remarkably lower in the diabetic patients in group 3 (1.30 ± 
0.35x10-•/min (µU/ml)) when compared with the relatives 
and healthy controls, but the differences were not statistically 
significant. Mean glucose effectiveness at basal insulin level 
(Sg) was not significantly different among the relatives in 
group 2 (2.38 ± 0.50), the healthy controls in group 1 (2.66 ± 
0.38) and the diabetic patients in group 3 (2.27± 0.49 x 10'2 / 
min). 
Conclusions. We conclude that (i) the pathogenetic mechanisms 
of type 2 diabetes in indigenous Ghanaians are characterised 
by severe beta cell dysfunction and moderate reduction in SL 
Although the healthy relatives manifest insulin resistance 
with compensatory hyperinsulinaemia, our study suggests 
that the conversion of such subjects to type 2 diabetes is 
determined by deterioration in beta cell function and perhaps 
Si but not tissue Sg in Ghanaians. Prospective studies are 
needed to examine the sequential changes that lead to the 
development of type 2 diabetes in indigenous Ghanaians. 
S Afr Med J 2002; 92: 377-384. 
The global epidemic of type 2 diabetes is of major concern to 
diabetologists and health care policy makers in developing and 
developed countries.1·3 The aetiology of the disease is unknown 
in most cases. It is well recognised that type 2 diabetes is a 
genetic and familial disease.'·5 The hallmark of this disease is 
insulin resistance and beta cell dysfunction in several 
populations.'·' The disease is very heterogeneous and the 
aetiologies may be different.'·17 It is well established that the 
respective contributions of the pathogenetic components of 
hyperglycaemia and type 2 diabetes vary considerably 
depending on the ethnicity and race of the populations. 
Previous studies have suggested that the prevalence of type 2 
diabetes was very low in West Africa18•19 and other parts of 
Africa.20 However, we have recently observed that the rate of 
mJ type 2 diabetes in 5 000 Ghanaians residing in Accra and 
surrounding suburbs is approaching 5% (A B G Amoah et al. -
unpublished observation). To the best of our knowledge, 
however, detailed anthropometric and metabolic 
characterisation of beta cell function and insulin action has not 
been undertaken in West Africans with and without type 2 
diabetes residing in their country of origin. 
Previous studies have indicated that non-diabetic first-degree 
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relatives of patients with type 2 diabetes and certain ethnic 
groups, e.g. African Americans, native Americans, etc., have an 
increased propensity for type 2 diabetes. 12·1'-'1·24 These studies 
have demonstrated that insulin resistance and 
hyperinsulinaemia occur in prediabetic offspring and first-
degree relatives of patients with type 2 diabetes.15•16 On the 
contrary, other authorities argue that beta cell dysfunction may 
be the primary disorder underlying type 2 diabetes. Therefore, 
we believe that metabolic and anthropometric studies of 
normoglycaemic, first-degree relatives could provide important 
insights into the pathophysiology of type 2 diabetes in 
Ghanaians. 
The aim of the present study was, therefore, to assess beta 
cell function, insulin sensitivity (Si) and glucose effectiveness 
(Sg) in patients with type 2 diabetes, non-diabetic first-degree 
relatives of Ghanaian patients (who are presumably genetically 
at greater risk for the disease) and healthy control subjects 
without family history of type 2 diabetes. 
SUBJECTS, MATERIALS AND METHODS 
Subjects 
The study included three Ghanaian populations, namely group 
1: 15 healthy control subjects who were glucose-tolerant 
Ghanaians without a family history of diabetes; group 2: 11 
glucose-tolerant Ghanaians who were first-degree relatives of 
patients with type 2 diabetes mellitus; and group 3: 10 patients 
with type 2 diabetes as defined by the World Health 
Organisation (WHO) criteria.25 All the subjects lived in the 
greater Accra metropolitan area, with a population of about 1.2 
million. The subjects were not members of the same family; The 
first-degree relatives were either offspring or siblings of 
patients with type 2 diabetes who were attending the 
University of Ghana Outpatient Diabetes Clinic, Korie Bu 
Teaching Hospital, Accra, Ghana. Patients with known type 2 
diabetes were defined as: (i) individuals who developed the 
disease after 40 years; (ii) individuals currently receiving oral 
glibenclamide or metformin for glycaemic control; and (iii) 
individuals who had never been admitted to the hospital for 
diabetic ketoacidosis. Individuals who received insulin were 
initially treated with a sulfonylurea or metformin for several 
years before converting to insulin therapy. Since type 1 
diabetes is generally uncommon in adult Ghanaians, we do 
not believe that any of our patients had type 1 diabetes. The 
non-diabetic healthy relatives were recruited or contacted 
through their parents and/or siblings followed by a personal 
visit to the homes of these subjects by one of the authors. This 
approach was adopted to ensure and ascertain that the subjects 
were first-degree relatives of our type 2 diabetic patients. The 
healthy control subjects were recruited from the same 
neighbourhoods and the medical complex as well as door-to-
door recruitment visits. The healthy control subjects were 
recruited only if to the best of their knowledge none of their 
family members or relatives had a diagnosis of diabetes. An 
'oral glucose tolerance test was not done in the case of parents 
or siblings of the healthy control subjects. Therefore, the lack 
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of biochemical ascertainment of parental diabetes or history of 
diabetes in the healthy controls could have resulted in 
misclassification of some of our healthy controls if their parents 
or siblings had pre-existing, asymptomatic, undiagnosed type 2 
diabetes. Apart from the diabetic patients who were taking 
either a sulfonylurea or metformin, subjects taking medications 
known to influence glucose and insulin metabolism were 
excluded from the study. The oral antidiabetic medications 
were discontinued 3 - 5 days before the metabolic studies. In 
addition, subjects known to have heart, renal and liver disease 
by history, physical examination and appropriate laboratory 
testing were excluded. Informed written consent approved by 
the Institutional Review Board for Human Research at the 
University of Ghana Medical School, Accra, Ghana was 
obtained from each subject after the risks entailed in the study 
had been thoroughly explained. Clinical characteristics of the 
three populations are shown in Table I. 
Table I. Clinical and biochemical parameters of non-diabetic first-
degree relatives of Ghanaian patients with type 2 diabetes 
mellitus and healthy controls (mean ± SEM) 
Type2 DM 
Parameter Controls Relatives patients 
Number 15 11 10 
Sex (f/m,%) 37 52 59 
Age (yrs) 36.5 ± 1.63 30.8 ± 1.5# 43.4 ± 1.3*** 
Bwt (kg) 68.6 ± 1.9 68.4 ± 2.5 71.2 ± 3.1 
Height (m) 1.6 ± 0.02 1.64 ± 0.01 1.66 ± 0.02 
BMl(kg/m') 26.9 ± 2.3 25.9 ± 1.6 26.0 ± 0.03 
LBM (%) 74.3 ± 1.6 73.4 ± 1.7 73.3 ± 2.1 
BFM(%) 25.7 ± 1.7 26.8 ± 1.7 27.2 ± 2.4 
WHR 0.86 ± 0.02 0.81±0.03# 0.90 ± 0.02*** 
Skinfold thickness (mm) 
Triceps 16.36 ± 1.72 19.21 ± 2.01 19.65 ± 1.88 
Biceps 7.53 ± 0.96 10.44 ± 1.59 11.80 ± 1.51** 
Scapular 16.50 ± 1.54 17.92 ± 2.02 20.56 ± 1.89** 
Subscapular 19.77 ± 1.90 23.02 ± 2.29 25.30 ± 2.27* 
Bwt = body weight; BMI = body mass index, LBM = lean body mass; 
BFM = body fat mass; WHR = weight-hip circumference ratios; NS = not 
statistically significant; DM = diabetes mellitus. 
*P < 0.05'DM v. controls. 
**P < 0.02, relatives v. controls 
#P < 0.05 and *** P < 0.001 DM v. relatives and controls. 
Study protocol 
After a 10 - 12-hour overnight fast subjects reported to the 
Diabetes Research Laboratory, Department of Medicine, 
University of Ghana Medical School. Body weight and height 
were measured with the subject wearing a very light gown and 
no shoes. Lean body mass and body fat composition were 
measured using the bioelectrical impedance analyser.26 Body fat 
distribution was measured as the waist-to-hip circumference 
ratio. The waist circumference was measured at the level of the 
umbilicus (with the subject in a supine position) and the hip 
circumference at the level of the greater trochanter (in the 
standing position). All the subjects answered a simple 
questionnaire on physical activity. Subjects who participated in 
endurance or competitive sport were excluded because of the 
effects of chronic strenuous exercise on insulin sensitivity. 
Metabolic studies 
With the subject in the supine position, two intravenous 
needles ('heparin lock') were inserted into the forearm veins 
and kept patent with 0.9% normal saline infusion. One 
intravenous line was used to draw blood samples and the 
other to administer the intravenous glucose and exogenous 
insulin. 
Oral glucose tolerance test (OGTT) 
Except for the diabetic patients, each subject was instructed to 
ingest at least 250 g carbohydrate in his or her regular meals 
for at least 3 days before the test. After the 10 - 12-hour 
overnight fast subjects ingested 75 g oral glucose load 
(Koladex, Baltimore, Md.) over a 2-minute period. Blood 
samples for serum glucose, insulin and C-peptide were 
obtained at baseline, t == 0 minutes, and 30, 60, 90, 120, 150, 
180, 210 and 240 minutes. The glucose tolerance status of the 
subjects was defined using the WHO criteria.27 
Frequently sampled intravenous glucose tolerance 
(FSIGT) test 
The insulin-modified frequently sampled intravenous glucose 
tolerance (FSIGT) test was performed in each subject.23-3° Four 
blood samples were obtained at t == -20, -10, -5, and 0 minutes 
for basal serum glucose, C-peptide and insulin concentrations. 
The average of the four samples was taken as the basal value. 
Thereafter, 0.3 g/kg glucose (50 ml of 50% dextrose water) was 
infused over a 1-minute period. At t == 19 minutes, intravenous 
insulin (0.05 U /kg, Humulin, Eli Lilly, Indianapolis, Ind.) 
dissolved in 30 ml of 0.9% normal saline was infused over 60 
seconds. Blood samples were obtained at frequent intervals at 
t == 2, 3, 4, 5, 6, 8, 10, 12, 16, 19, 22, 24, 25, 27, 30, 40, 60, 70, 90, 
120, 140, 150, 160 and 180 minutes for serum glucose, 
C-peptide and insulin concentrations. All the samples were 
centrifuged at 4°C and the sera were frozen and stored at-20°C 
until assayed. 
Analytical methods 
Serum glucose concentrations were measured by the glucose 
oxidase method using a glucose autoanalyser (Beckman 
Instruments, Fullerton, Calif.). The serum insulin and 
C-peptide levels of each individual were determined by a IDJ 
standard double antibody radio-immunoassay technique in the 
same assay at the Core Laboratories of the Ohio State 
University Hospitals. The sensitivity of the insulin assay was 
2.5 mU /1. The intra- and inter-assay coefficients of variation 
(CV) were 6% and 10%, respectively. The lower limit of the 
C-peptide assay was 0.47 ng/ml (0.02 nmol/ml) and the intro-
and inter-assay CVs were 7% and 13%, respectively. The 
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C-peptide assay did not cross with the insulin assay. In 
contrast, our insulin cross-reacted 100% with proinsulin (PI). 
However, we have previously found (unpublished personal 
observation) that the per cent contribution of Pl, using a 
specific Pl assay, to the total immunoreactive insulin ORD is 
less than 10%. Therefore the absolute contribution to the total 
IRI in normal subjects is quantitatively very small. 
Calculations and statistical analyses 
Results are expressed as mean± standard error of mean (SEM), 
unless stated otherwise. The body mass index (BMI) was 
calculated as weight (kg) divided by height (m2). Obesity was 
taken as BMI greater than 30 kg/m2 for females and males. The 
acute first (t = 0 - 5 minutes) and second (t = 8 - 19 minutes) 
phases of insulin release were calculated as the area under the 
curves (AUC) for insulin and C-peptide responses above the 
baseline values using the trapezoidal rule. Note that during 
routine FISGT tests the acute second phase insulin areas are 
often estimated as the time between t =10 - 60 minutes. In the 
present study this was abbreviated to 19 minutes because of 
the administration of exogenous insulin at t = 19 minutes. The 
insulin sensitivity index (Si) and glucose effectiveness (Sg) 
were calculated using the minimal model software program 
MlNMOD (copyright, Dr Richard Bergman).29•30 Step-wise linear 
regression and two-way analyses of covariance (ANOCOVA) 
were used to adjust for the effects of age, sex, body weight and 
waist/hip ratio (WHR) on the various metabolic parameters. 
Linear regression and correlation coefficients were calculated 
using the least squares method. The non-parametric data were 
analysed using chi-square and Mann-Whitney rank tests. 
Statistical analyses were performed using the Student's t-test 
(unpaired) and ANOVA, where appropriate, with the 
Bonferroni method for post hoc testing. For comparison of the 
mean data with unequal variance, the Neuman-Keuls multiple 
t-test was used. Probability (P) value less than 0.05 was 
considered statistically significant. 
RESULTS 
Clinical characteristics 
As shown in Table I, the mean age tended to be highest in the 
group 3 type 2 diabetic patients, intermediate in the group 1 
healthy controls and lowest in the group 2 healthy relatives. 
The younger age of the relatives reflects the fact that most of 
our type 2 diabetic parents began having children in their 20s, 
similar to most Ghanaian women. Despite similar BMls and 
lean body mass, the WHR (a surrogate of upper body obesity) 
and tricep and bicep skinfolds were significantly higher in the 
type 2 diabetic patients (group 3), intermediate in healthy 
controls (group 1) and lowest in the first-degree relatives 
(group 2). Similarly, the per cent body fat mass was highest in 
the type 2 diabetic patients, intermediate in the healthy 
relatives and lowest in the healthy controls. 
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Oral glucose tolerance test 
Mean fasting serum glucose levels were similar in the healthy 
control group and relatives (4.3 ± 0.2 v. 4.2 ± 0.2 mmol/l). The 
mean fasting serum glucose level was 7.2 ± 0.6 mmol/l in the 
type 2 diabetic patients (Fig. IA, and Table II). After the oral 
glucose challenge the serum glucose responses and AUCs were 
higher in the group 3, type 2 diabetic patients than in the non-
diabetic groups. Mean AUCs for serum glucose were similar in 
the first-degree relatives v. healthy control subjects (Fig. IA, 
and Table II). Mean fasting serum insulin levels were 
comparable among the three groups (Table II, Fig. lB). 
Following the oral glucose challenge, serum insulin levels were 
significantly higher (P < 0.05, and P < 0.001) at 30 and 90 
minutes in the first-degree relatives than in the healthy controls 
(Table II, Fig. lB). The group 3 type 2 diabetic patients had 
severely blunted incremental AUC values for insulin responses 
when compared with groups I and 2. Therefore the 
insulin/ glucose ratios were significantly lower in group 3 
when compared with the non-diabetic groups. Mean serum 
C-peptide responses followed a trend similar to those of the 
insulin responses in the three groups (Table II and Fig. IC). 
Table II. Acute early serum glucose, insulin and C-peptide levels 
during oral tolerance in Ghanaians with varying degrees of 
glucose tolerance (mean ± SEM) 
Parameter Controls 
Glucose (mmol/J) 
Omins 4.3 ± 0.2 
30mins 6.3± 0.4 
AUC* 501±61 
Insulin (µU /1) 
Omins 23.5 ± 3.0 
30 mins 69.0 ± 7.8 
AUCt 9343± 1289 
C-peptide (nmol/ml) 
Omins 0.44 ± 0.04 
30 mins 1.16 ± 0.11 
AUC* 175 ± 15 
*AUC = mmol/I x mins. 
tAUC= pmol/ml x mins; 
:j:AUC = nmol/ml x mins 
§P < 05, relatives v. controls. 
Relatives 
4.2 ± 0.2 
6.6 ± 0.2 
513 ± 61 
24.7± 1.3 
77.0 ± 6.0 
11286±1 065 
0.48 ± 0.03 
1.44 ± 0.11 
267 ± 19§ 
'l[P < 0.001, DM patients v. relatives and controls. 
"P < 0.001, DM patients v. relatives and controls. 
ADC = area under the curve; OM= diabetes mellitus. 
Type2 DM 
patients 
7.2 ± 0.6'11 
9.8 ± 0.6'11 
1 019 ± g7'II 
8.9±1.71 
22.7 ± 75'll 
3441±643'1 
0.41±0.04 
o.92 ± om'II 
115 ± 171! 
Frequently sampled intravenous glucose tolerance 
test 
After intravenous glucose administration, mean glucose rose to 
peak levels of 15.4 ± 2.0 and 13.1 ± 1.2 mmol/l and 15.24 ± 
1.4 mmol/l in the relatives, healthy controls and diabetic 
·patients, respectively (Table III, Fig. 2A). Following the 
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Fig. 1. Mean ± SEM serum glucose (A), insulin (B) and C-peptide 
(C) levels before and during the oral glucose tolerance test in 
Ghanaian healthy controls with normal glucose tolerance (closed 
squares), first-degree relatives of patients with type 2 diabetes 
mellitus (closed circles), and type 2 diabetes mellitus patients (closed 
triangles). *P < 0.05 relatives v. healthy controls, ***P < 0.001 
diabetics v. relatives and healthy controls. (To convert insulin to 
pmol/ml, multiply by 6, to convert glucose to mmol/ml divide by 18, 
and to convert C-peptide to nmol/ml, multiply by 0.33.) 
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Fig. 2. Mean± SEM serum glucose (A), insulin (B) and C-peptide 
(C) levels before and during the oral glucose tolerance test in 
Ghanaian healthy controls with normal glucose tolerance (closed 
squares), first-degree relatives of patients with type 2 diabetes 
mellitus (closed circles), and type 2 diabetes mellitus patients (closed 
triangles). *P < 0.05 relatives v. healthy controls, ***P < 0.001 
diabetics v. relatives and healthy controls. (To convert insulin to 
pmol/ml multiply by 6, to convert glucose to mmol/ml divide by 18, 
and to convert C-peptide to nmol/ml multiply by 0.33.) 
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Table Ill. Acute first and second phase serum insulin and C-peptide secretion following FSIGT tests in non-diabetic first-degree relatives of 
Ghanaian patients with type 2 diabetes mellitus, patients with type 2 diabetes and healthy controls. (mean± SEM) 
DM 
OM Controls v. patients v. controls 
Parameters Controls Relatives relatives and relatives 
Acute responses (QGTT) 
Insulin (mU /1) 
Omins 26.1±3.8.4 28.9 ± 4.8 6.8 ± 1.0 0.095 0.001 
Peak 131.2 ± 34 147.8 ± 26 27.1 ± 16 0.001 0.001 
C-peptide (nmol/ml) 
Omins 0.36 ± 0.D3 0.38 ± 0.03 0.33 ± 0.04 NS NS 
Peak 1.18 :t 0.19 1.60 ± 0.15 0.56 ± 0.230 0.002 0.001 
Areas under curve (AUC) 
First phase (FSIGT) 
Insulin (mU /l x mins) 122 ± 75 320 ± 11.7 7.80 ±5.7 0.01 0.001 
C-peptide (nmol/ml x mins) 7.2 ± 1.1 12.7 ± 3.27 2.66 ± 2.29 0.130 0.001 
Second phase (FSIGT) 
(Insulin (µU/ml x mins) 9 8731±2 025 14 656 ± 2 930 10120± 1 725 NS NS 
C-peptide (nmol/ml x mins) 8.9±1.3 71.2 ± 12.4 14.9±1.4 0.001 0.170 
OGTT = oral glucose tolerance test; FSIGT = frequently sampled intravenous glucose tolerance test; DM = diabetes mellitus; NS = not significant. 
Table IV. Minimal model derived insulin sensitivity (Si) index and glucose effectiveness (Sg) at basal insulin in healthy controls and first· 
degree relatives of Ghanaian patients with type 2 diabetes meUitus (mean ±. SEM) 
Parameters 
Si (x 10/4 /min/(mU/l) 
Sg (x 10/-2 /min) 




intravenous glucose load, the mean serum insulin responses 
(acute first and second phases) as assessed by the absolute and 
incremental AUCs were greater but not significantly different 
in the first-degree relatives and healthy controls (Table III, Fig. 
2B). Both acute phases of insulin secretion were severely 
blunted in the type 2 diabetic patients when compared with the 
relatives and healthy controls. Mean serum C-peptide 
responses and AUCs followed patterns similar to those of the 
insulin profiles in the three groups (Table II, Fig. 2C). 
Minimal model parameters 
As shown in Table IV, the mean Si was lowest in the type 2 
diabetic patients, intermediate in the relatives and highest in 
the healthy controls, but the difference was not significant (P = 
NS) among the relatives and healthy controls and diabetic 
patients receiving active antidiabetic therapy. The mean Sg was 
not significantly different in the type 2 diabetic patients, 
healthy first-degree relatives and healthy control subjects. 
DISCUSSION 
Type 2 diabetes has become a global epidemic in several 
populations, especially in developing countries.1-3 Among 
people of West African ancestry, the prevalence of type 2 
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Relatives 
1.72 ± 0.32 
2.38 ± 0.50 
Type2DM 
patients 
1.30 ± 0.35 
2.27 ± 0.49 
NS 
NS 
diabetes varies depending on whether these individuals reside 
in urban or rural areas or Western industrialised versus 
developing countries.31-'2 Although type 2 diabetes is the 
commonest type of diabetes in the world, it is clearly a 
heterogeneous disease with varying phases of presentation. It 
is now clear that type 2 diabetes and its long-term 
complications have strong genetic and environmental 
components which differ among various populations. In this 
regard, we have recently observed increasing prevalence of 
type 2 diabetes and its associated long-term morbidity and 
mortality in our Ghanaian population.18•19 
In the present study we examined the various components of 
hyperglycaemia in indigenous Ghanaians residing in their 
native country. We felt that the study could shed light on the 
mechanism(s) of type 2 diabetes in indigenous Ghanaians since 
we have previously demonstrated33 that insulin secretion and 
insulin sensitivity in Ghanaian immigrants with and without 
type 2 diabetes and impaired glucose tolerance (IGT) are 
similar to those of African Americans residing in the USA. 
Furthermore, we were also interested to examine the 
importance of genetically mediated antecedent metabolic risk 
factors for type 2 diabetes in indigenous Ghanaians, which 
have been well described in previous studies of Caucasians 
and other high-risk populations.12-16 
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The present study demonstrated that the diabetic patients 
previously treated with either metformin or a sulfonylurea 
manifested moderately severe hyperglycaemia during fasting 
and after glucose challenge, as one would expect. In contrast, 
the serum glucose responses were similar in the relatives and 
healthy controls. We observed that hyperglycaemia in the 
Ghanaian patients with type 2 diabetes occurred at the expense 
of a severe beta cell dysfunction. During OGTT the serum 
insulin and C-peptide responses were 60% and 70% lower in 
the diabetic patients when compared with the healthy controls 
and the relatives, respectively. These findings are, however, 
similar to those reported in several other populations, 
including Ghanaian immigrants and African Americans 
residing in the USA.3336 Comparing the relatives and healthy 
controls, we found that after glucose challenge the mean 
stimulated absolute serum insulin and C-peptide responses 
were significantly greater in the relatives than in the healthy 
controls by ANOVA. These findings were also similar to our 
previous observations of healthy African Americans with and 
without a family history of type 2 diabetes residing in the 
USA,3'·36 and those of other ethnic groups.37•40 The present 
metabolic findings in the relatives (albeit cross-sectional) 
would support genetic inheritance as the major determinant of 
beta cell insulin secretion in indigenous Ghanaians residing in 
their native country. Nevertheless, our data could also indicate 
that other genetic and/ or environmental factors promote or 
induce beta cell dysfunction and precipitate the development 
of type 2 diabetes in Ghanaian individuals at greater risk for 
the disease. 
Several previous studies"·" have indicated that insulin 
secretion is genetically inherited. Indeed, the lost or blunted 
acute first phase insulin secretion in response to glucose 
stimulation is regarded as one of the earliest lesions in the 
pathogenesis of type 2 diabetes in several populations.'·10•33•3' 
We have previously demonstrated"·" loss of the acute first 
phase in African Americans and Ghanaian immigrants with 
impaired glucose tolerance and mild type 2 diabetes living in 
the USA. In this regard only few studies have examined the 
acute phases of insulin release in West Africans residing in 
their native country.24 In the present study we found that the 
acute first phase of insulin secretion was blunted in the 
Ghanaians with type 2 diabetes. In contrast, the acute first 
phase was exaggerated in the first-degree relatives, 
demonstrating that early beta cell dysfunction is unlikely to be 
the primary lesion in Ghanaians with type 2 diabetes. Our 
present study of Ghanaian relatives is somewhat in contrast to 
the findings of Ezenwaka et al. 24 who found a lower acute first 
phase insulin secretion in the healthy, lean non-diabetic first-
degree relatives of their Nigerian type 2 diabetic patients when 
compared with those without family history. We should note, 
however, that the Nigerian relatives were mostly males and 
had BMis of 22 kg/m2 when compared with the Ghanaians in 
the present study with an average BMI of 26 kg/m'. Therefore, 
similar to other populations, obesity appears to influence the 
beta cell secretion in individuals of West African ancestry. We 
should also note that some studies of healthy Caucasian first-
degree relatives13" 2 have demonstrated that the acute first phase 
of insulin release is either elevated or intact when compared 
with the first phase of those without family history of type 2 
diabetes. In summary, our findings in the Ghanaians residing 
in their native country are consistent with those of other 
populations with regard to the role of beta cell dysfunction in 
the aetiopathogenesis of type 2 diabetes. 
Previous studies have demonstrated that insulin resistance is 
the primary lesion underlying type 2 diabetes in these 
populations,6·'·'-1'"1 " but these findings are not uniform."·45 Some 
of these previous studies1'·1' have confirmed that insulin 
resistance precedes the development of type 2 diabetes by 
decades. Osei et al.33-3' have previously demonstrated insulin 
resistance in Ghanaian immigrants and/ or African Americans 
residing in the USA with impaired glucose tolerance and mild 
type 2 diabetes when compared with healthy control subjects. 
Furthermore, healthy Ghanaian immigrants and African 
Americans residing in the same environment manifest similar 
degrees of Si index." Because both populations originated from 
West Africa, i.e. remote and recent migrants, it was important 
to conduct studies among Ghanaians living in Ghana. In the 
present study we found that the indigenous Ghanaians with 
type 2 diabetes had an Si index 30% and 40% lower than the 
relatives and healthy controls, respectively. The lack of 
statistically significant difference in Si among the three groups 
is difficult to explain. We offer likely explanations for our 
findings. 
First, we strongly believe that the physical activity levels 
and/ or dietary factors (high fibre/ complex carbohydrate and 
low-fat diet) which are known to influence Si could be 
involved. Second, unlike sulfonylureas, metformin has been 
demonstrated to improve insulin sensitivity in some previous 
studies, but the results have been inconsistent. Because our 
patients received either glibenclamide (N = 5) or metformin 
(N = 5), it could be inferred that these drugs could have a 
variable impact on insulin sensitivity indices in our diabetic 
population. Third, we have previously demonstrated that 
insulin sensitivity is remarkably lower in Ghanaian immigrants 
in the USA with untreated type 2 diabetes. We found that the 
average Si was 0.6 ± 0.4 x 10·'/min/(uU/ml) in Ghanaian 
immigrants with untreated type 2 diabetes. Thus, we might 
have overestimated the severity of insulin resistance in our 
type 2 diabetic population in the present study of indigenous 
Ghanaians who had previously been treated with oral 
antidiabetic medications.36 Fourth, obesity has been associated 
with insulin resistance and worsens the genetically mediated 
insulin resistance in individuals with and without type 2 
sr.ni •. diabetes. In this regard, Taniguchi et al."·45 indicated that in a:g 
Japanese patients with type 2 diabetes and impaired glucose 
tolerance, obesity was a major determinant of insulin 
sensitivity as assessed by the FSIGT and Bergman's minimal 
model method, similar to the present study. Regarding blacks, 
Banergi and Lebovitz17 have reported that non-obese (BMI less 
than 27 kg/m') African American patients with type 2 diabetes 
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had a normal or preserved insulin sensitivity similar to that 
in the present study of Ghanaians. Indeed, in the present 
study the BMls were 26.9, 25.9 and 26.0 kg/m' for the healthy 
controls, relatives and type 2 diabetic patients, respectively. 
Therefore, we believe that our Ghanaians with type 2 diabetes 
could perhaps represent the so-called insulin-sensitive variant 
of type 2 diabetes previously reported in black Americans.17 
Normal glucose tolerance is achieved by both insulin-
mediated and glucose-mediated glucose disposal in vivo in 
humans. This ability of glucose to mediate its own disposal is 
referred to as glucose effectiveness (Sg),27-29 Previous 
investigators44,45 have reported that Sg is reduced in patients 
with IGT and type 2 diabetes. However, previous studies from 
our laboratory and those of others have suggested that Sg is 
intact or increased in prediabetics and offspring of patients 
with type 2 diabetes. We have previously demonstrated33•35·"" 
that Sg is not significantly altered in patients with IGT and 
type 2 diabetes in recent Ghanaian immigrants and African 
Americans living in the USA. In our present study we found 
that Sg at basal insulin was not statistically different in the 
three groups. It is of interest to note that Sg values in our non-
diabetic and diabetic African Americans and recent Ghanaian 
immigrants residing in the USA were similar to those of the 
native Ghanaians in the present study. Therefore, Sg appears to 
be robust and well preserved in people of West African origin 
residing in diverse environments. The biological significance 
and the reasons for the preserved Sg in these black populations 
with varying degrees of glucose tolerance living in diverse 
populations remains to be elucidated. 
In summary, the present study demonstrates that severe beta 
cell dysfunction and moderate insulin resistance, but not tissue 
glucose resistance, characterise the hyperglycaemia in 
Ghanaians with type 2 diabetes. Although our study was cross-
sectional, we are tempted to infer from the metabolic findings 
in the first-degree relatives of the Ghanaian patients with type 
2 diabetes that insulin resistance/hyperinsulinaemia and not 
beta cell dysfunction appears to be the primary or earliest 
lesion underlying type 2 diabetes in Ghanaians. These 
pathogenetic mechanisms are similar to those reported in 
African Americans and recent Ghanaian immigrants residing in 
the USA. 
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